Stern Dana Kaslow, Lebwohl Mark
Mount Sinai Medical Center, One Gustave L. Place, New York, NY 10029, USA.
J Drugs Dermatol. 2002 Sep;1(2):134-6.
Bexarotene has recently been approved in the United States and Europe as a single orally administered retinoid for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. We describe a 47-year old female with a 4-year history of mycosis fungoides (MF) who developed debilitating side effects from acitretin and PUVA, and subsequently responded to bexarotene 75 mg orally once daily combined with PUVA. Bexarotene has been approved at an optimal starting dose of 300 mg/m2/d but has not yet been approved for use in combination with PUVA. We used a low dose (75 mg) combined with PUVA in an attempt to minimize side effects while maintaining treatment efficacy. Our patient's response to a novel regimen of low dose bexarotene combined with PUVA has been excellent and suggests that this regimen may be a useful method for treatment of MF.
贝沙罗汀最近在美国和欧洲被批准作为一种口服单一类视黄醇药物，用于治疗对至少一种先前全身治疗无效的皮肤T细胞淋巴瘤（CTCL）患者。我们描述了一名47岁女性，有4年蕈样肉芽肿（MF）病史，她因阿维A和补骨脂素紫外线A光化学疗法（PUVA）出现了使人衰弱的副作用，随后对每日一次口服75毫克贝沙罗汀联合PUVA治疗有反应。贝沙罗汀已被批准的最佳起始剂量为300毫克/平方米/天，但尚未被批准与PUVA联合使用。我们使用低剂量（75毫克）联合PUVA，试图在维持治疗效果的同时尽量减少副作用。我们的患者对低剂量贝沙罗汀联合PUVA的新方案反应良好，这表明该方案可能是治疗MF的一种有用方法。
